EGFRvIII-specific chimeric antigen receptor T cells migrate to and kill tumor deposits infiltrating the brain parenchyma in an invasive xenograft model of glioblastoma

PLoS ONE

Volumn 9, Issue 4, 2014, Pages

  Miao, Hongsheng ^a   Choi, Bryan D ^a   Suryadevara, Carter M ^a   Sanchez Perez, Luis ^a   Yang, Shicheng ^a   De Leon, Gabriel ^a   Sayour, Elias J ^a   McLendon, Roger ^a   Herndon II, James E ^a   Healy, Patrick ^a   Archer, Gary E ^a   Bigner, Darell D ^a   Johnson, Laura A ^a,b   Sampson, John H ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR ANTIBODY; T LYMPHOCYTE RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR VIII; GREEN FLUORESCENT PROTEIN; LYMPHOCYTE ANTIGEN RECEPTOR; TUMOR ANTIGEN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN EXPRESSION; ANTINEOPLASTIC ACTIVITY; ARTICLE; BRAIN TISSUE; CANCER INFILTRATION; CANCER INHIBITION; CELL MIGRATION; CELL THERAPY; CELLULAR DISTRIBUTION; CLINICAL FEATURE; CONTROLLED STUDY; EPIDERMAL GROWTH FACTOR RECEPTOR 8 SPECIFIC CHIMERIC ANTIGEN RECEPTOR T LYMPHOCYTE; GLIOBLASTOMA; GROWTH INHIBITION; HUMAN; HUMAN CELL; IN VITRO STUDY; MOUSE; NONHUMAN; PARENCHYMA; SURVIVAL; T LYMPHOCYTE; TUMOR GROWTH; TUMOR INVASION; TUMOR REGRESSION; ADOPTIVE TRANSFER; ANIMAL; BRAIN; BRAIN NEOPLASMS; CANCER TRANSPLANTATION; CELL MEMBRANE; CELL MOTION; FEMALE; GENETICS; IMMUNOLOGY; IMMUNOTHERAPY; LENTIVIRINAE; METABOLISM;

ADOPTIVE TRANSFER; ANIMALS; ANTIGENS, NEOPLASM; BRAIN; BRAIN NEOPLASMS; CELL MEMBRANE; CELL MOVEMENT; FEMALE; GLIOBLASTOMA; GREEN FLUORESCENT PROTEINS; HUMANS; IMMUNOTHERAPY; LENTIVIRUS; MICE; NEOPLASM INVASIVENESS; NEOPLASM TRANSPLANTATION; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTORS, ANTIGEN, T-CELL; T-LYMPHOCYTES;

EID: 84899523433     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0094281     Document Type: Article

References (51)

1. Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, et al. (2005) Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352: 987-996. (Pubitemid 40349501)
2. Imperato JP, Paleologos NA, Vick NA (1990) Effects of treatment on long-term survivors with malignant astrocytomas. Ann Neurol 28: 818-822.
3. Johnson LA, Morgan RA, Dudley ME, Cassard L, Yang JC, et al. (2009) Gene therapy with human and mouse T-cell receptors mediates cancer regression and targets normal tissues expressing cognate antigen. Blood 114: 535-546.
4. Hong JJ, Rosenberg SA, Dudley ME, Yang JC, White DE, et al. (2010) Successful treatment of melanoma brain metastases with adoptive cell therapy. Clin Cancer Res 16: 4892-4898.
5. Robbins PF, Morgan RA, Feldman SA, Yang JC, Sherry RM, et al. (2011) Tumor regression in patients with metastatic synovial cell sarcoma and melanoma using genetically engineered lymphocytes reactive with NY-ESO-1. J Clin Oncol 29: 917-924.
6. Rosenberg SA (2011) Cell transfer immunotherapy for metastatic solid cancer - what clinicians need to know. Nat Rev Clin Oncol 8: 577-585.
7. Kochenderfer JN, Dudley ME, Feldman SA, Wilson WH, Spaner DE, et al. (2012) B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cells. Blood 119: 2709-2720.
8. Rosenberg SA, Yang JC, Robbins PF, Wunderlich JR, Hwu P, et al. (2003) Cell transfer therapy for cancer: lessons from sequential treatments of a patient with metastatic melanoma. J Immunother 26: 385-393. (Pubitemid 37128550)
9. Zitvogel L, Tesniere A, Kroemer G (2006) Cancer despite immunosurveillance: immunoselection and immunosubversion. Nat Rev Immunol 6: 715-727. (Pubitemid 44453458)
10. Kalos M, June CH (2013) Adoptive T cell transfer for cancer immunotherapy in the era of synthetic biology. Immunity 39: 49-60.
11. Lamers CH, Sleijfer S, Vulto AG, Kruit WH, Kliffen M, et al. (2006) Treatment of metastatic renal cell carcinoma with autologous T-lymphocytes genetically retargeted against carbonic anhydrase IX: first clinical experience. J Clin Oncol 24: e20-22.
12. Till BG, Jensen MC, Wang J, Qian X, Gopal AK, et al. (2012) CD20-specific adoptive immunotherapy for lymphoma using a chimeric antigen receptor with both CD28 and 4-1BB domains: pilot clinical trial results. Blood 119: 3940-3950.
13. Pule MA, Savoldo B, Myers GD, Rossig C, Russell HV, et al. (2008) Virus-specific T cells engineered to coexpress tumor-specific receptors: persistence and antitumor activity in individuals with neuroblastoma. Nat Med 14: 1264-1270.
14. Brentjens RJ, Davila ML, Riviere I, Park J, Wang X, et al. (2013) CD19-targeted T cells rapidly induce molecular remissions in adults with chemotherapy-refractory acute lymphoblastic leukemia. Sci Transl Med 5: 177ra138.
15. Porter DL, Levine BL, Kalos M, Bagg A, June CH (2011) Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. N Engl J Med 365: 725-733.
16. Brentjens R, Yeh R, Bernal Y, Riviere I, Sadelain M (2010) Treatment of chronic lymphocytic leukemia with genetically targeted autologous T cells: case report of an unforeseen adverse event in a phase I clinical trial. Mol Ther 18: 666-668.
17. Morgan RA, Yang JC, Kitano M, Dudley ME, Laurencot CM, et al. (2010) Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2. Mol Ther 18: 843-851.
18. Wikstrand CJ, Hale LP, Batra SK, Hill ML, Humphrey PA, et al. (1995) Monoclonal antibodies against EGFRvIII are tumor specific and react with breast and lung carcinomas and malignant gliomas. Cancer Res 55: 3140-3148.
19. Heimberger AB, Hlatky R, Suki D, Yang D, Weinberg J, et al. (2005) Prognostic effect of epidermal growth factor receptor and EGFRvIII in glioblastoma multiforme patients. Clin Cancer Res 11: 1462-1466. (Pubitemid 40315227)
20. Wong AJ, Ruppert JM, Bigner SH, Grzeschik CH, Humphrey PA, et al. (1992) Structural alterations of the epidermal growth factor receptor gene in human gliomas. Proc Natl Acad Sci U S A 89: 2965-2969.
21. Engelhardt B (2006) Molecular mechanisms involved in T cell migration across the blood-brain barrier. Journal of Neural Transmission 113: 477-485.
22. Banks WA, Erickson MA (2010) The blood-brain barrier and immune function and dysfunction. Neurobiology of Disease 37: 26-32.
23. Rascher G, Fischmann A, Kroger S, Duffner F, Grote EH, et al. (2002) Extracellular matrix and the blood-brain barrier in glioblastoma multiforme: spatial segregation of tenascin and agrin. Acta Neuropathol 104: 85-91. (Pubitemid 36075363)
24. Ajay D, Sanchez-Perez L, Choi BD, De Leon G, Sampson JH (2012) Immunotherapy with tumor vaccines for the treatment of malignant gliomas. Curr Drug Discov Technol 9: 237-255.
25. Claes A, Idema AJ, Wesseling P (2007) Diffuse glioma growth: a guerilla war. Acta Neuropathol 114: 443-458. (Pubitemid 47521501)
26. Giese A, Westphal M (1996) Glioma invasion in the central nervous system. Neurosurgery 39: 235-250; discussion 250-232.
27. Agarwal S, Manchanda P, Vogelbaum MA, Ohlfest JR, Elmquist WF (2013) Function of the blood-brain barrier and restriction of drug delivery to invasive glioma cells: findings in an orthotopic rat xenograft model of glioma. Drug Metab Dispos 41: 33-39.
28. Vauleon E, Avril T, Collet B, Mosser J, Quillien V, et al. (2010) Overview of Cellular Immunotherapy for Patients with Glioblastoma. Clinical and Developmental Immunology 2010.
29. Hashizume R, Ozawa T, Dinca EB, Banerjee A, Prados MD, et al. (2010) A human brainstem glioma xenograft model enabled for bioluminescence imaging. J Neurooncol 96: 151-159.
30. Miura FK, Alves MJ, Rocha MC, da Silva R, Oba-Shinjo SM, et al. (2010) Xenograft transplantation of human malignant astrocytoma cells into immunodeficient rats: an experimental model of glioblastoma. Clinics (Sao Paulo) 65: 305-309.
31. Candolfi M, Curtin JF, Nichols WS, Muhammad AG, King GD, et al. (2007) Intracranial glioblastoma models in preclinical neuro-oncology: neuropathological characterization and tumor progression. J Neurooncol 85: 133-148. (Pubitemid 47629395)
32. Bigner SH, Humphrey PA, Wong AJ, Vogelstein B, Mark J, et al. (1990) Characterization of the epidermal growth factor receptor in human glioma cell lines and xenografts. Cancer Res 50: 8017-8022.
33. Nishikawa R, Ji XD, Harmon RC, Lazar CS, Gill GN, et al. (1994) A mutant epidermal growth factor receptor common in human glioma confers enhanced tumorigenicity. Proc Natl Acad Sci U S A 91: 7727-7731. (Pubitemid 24238258)
34. Lal A, Glazer CA, Martinson HM, Friedman HS, Archer GE, et al. (2002) Mutant epidermal growth factor receptor up-regulates molecular effectors of tumor invasion. Cancer Res 62: 3335-3339. (Pubitemid 34651373)
35. Morgan RA, Johnson LA, Davis JL, Zheng Z, Woolard KD, et al. (2012) Recognition of glioma stem cells by genetically modified T cells targeting EGFRvIII and development of adoptive cell therapy for glioma. Hum Gene Ther 23: 1043-1053.
36. Santos EB, Yeh R, Lee J, Nikhamin Y, Punzalan B, et al. (2009) Sensitive in vivo imaging of T cells using a membrane-bound Gaussia princeps luciferase. Nat Med 15: 338-344.
37. Sadelain M, Brentjens R, Riviere I (2013) The basic principles of chimeric antigen receptor design. Cancer Discov 3: 388-398.
38. Choi BD, Suryadevara CM, Gedeon PC, Herndon Ii JE, Sanchez-Perez L, et al. (2014) Intracerebral delivery of a third generation EGFRvIII-specific chimeric antigen receptor is efficacious against human glioma. J Clin Neurosci 21: 189-190.
39. Engelhardt B, Ransohoff RM (2012) Capture, crawl, cross: the T cell code to breach the blood-brain barriers. Trends Immunol 33: 579-589.
40. Ransohoff RM (2009) Chemokines and chemokine receptors: standing at the crossroads of immunobiology and neurobiology. Immunity 31: 711-721.
41. Mestas J, Hughes CC (2004) Of mice and not men: differences between mouse and human immunology. J Immunol 172: 2731-2738. (Pubitemid 38263654)
42. Grupp SA, Kalos M, Barrett D, Aplenc R, Porter DL, et al. (2013) Chimeric antigen receptor-modified T cells for acute lymphoid leukemia. N Engl J Med 368: 1509-1518.
43. Sampson JH, Heimberger AB, Archer GE, Aldape KD, Friedman AH, et al. (2010) Immunologic escape after prolonged progression-free survival with epidermal growth factor receptor variant III peptide vaccination in patients with newly diagnosed glioblastoma. J Clin Oncol 28: 4722-4729.
44. Butterfield LH, Ribas A, Dissette VB, Amarnani SN, Vu HT, et al. (2003) Determinant spreading associated with clinical response in dendritic cell-based immunotherapy for malignant melanoma. Clin Cancer Res 9: 998-1008. (Pubitemid 36323703)
45. Hughes MS, Yu YY, Dudley ME, Zheng Z, Robbins PF, et al. (2005) Transfer of a TCR gene derived from a patient with a marked antitumor response conveys highly active T-cell effector functions. Hum Gene Ther 16: 457-472. (Pubitemid 40647143)
46. Morgan RA, Dudley ME, Yu YY, Zheng Z, Robbins PF, et al. (2003) High efficiency TCR gene transfer into primary human lymphocytes affords avid recognition of melanoma tumor antigen glycoprotein 100 and does not alter the recognition of autologous melanoma antigens. J Immunol 171: 3287-3295. (Pubitemid 37093556)
47. Riddell SR, Greenberg PD (1990) The use of anti-CD3 and anti-CD28 monoclonal antibodies to clone and expand human antigen-specific T cells. J Immunol Methods 128: 189-201. (Pubitemid 20120262)
48. Yang S, Cohen CJ, Peng PD, Zhao Y, Cassard L, et al. (2008) Development of optimal bicistronic lentiviral vectors facilitates high-level TCR gene expression and robust tumor cell recognition. Gene Ther 15: 1411-1423.
49. Yoshimoto K, Dang J, Zhu S, Nathanson D, Huang T, et al. (2008) Development of a real-time RT-PCR assay for detecting EGFRvIII in glioblastoma samples. Clin Cancer Res 14: 488-493. (Pubitemid 351226117)
50. Sampson JH, Choi BD, Sanchez-Perez L, Suryadevara CM, Snyder DJ, et al. (2013) EGFRvIII mCAR-modified T cell therapy cures mice with established intracerebral glioma and generates host immunity against tumor-antigen loss. Clin Cancer Res.
51. Szentirmai O, Baker CH, Lin N, Szucs S, Takahashi M, et al. (2006) Noninvasive bioluminescence imaging of luciferase expressing intracranial U87 xenografts: correlation with magnetic resonance imaging determined tumor volume and longitudinal use in assessing tumor growth and antiangiogenic treatment effect. Neurosurgery 58: 365-372; discussion 365-372.